Astrazeneca PLC 6-K, filed Jul 29, 2022
Astrazeneca PLC (AZN)
6-K
2022-07-29
For: 2022-07-29
View Original
Added on
April 02, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on July 29, 2022.
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of July 2022
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Chair succession
29 July 2022 07:01 BST
Michel Demaré to succeed Leif Johansson as
Non-Executive Chair of the Board
AstraZeneca PLC today announced the appointment of Michel
Demaré as the Chair-designate of the Board.
His appointment followed a robust succession planning process led
by Philip Broadley in his capacity as senior independent
Non-Executive Director.
As previously communicated, Leif Johansson, current Chair of the
Board of AstraZeneca will be retiring at the conclusion of the
Company's Annual General Meeting in April 2023. Michel's
appointment will take effect immediately on Leif's retirement
allowing for a managed handover period over the coming
months.
Michel was appointed to the Board of AstraZeneca in September 2019
as an independent Non-Executive Director and is currently Chair of
the Company's Remuneration Committee and member of the Audit
Committee and the Nomination and Governance Committee. He is
a Non-Executive Director of Vodafone Group Plc and Louis Dreyfus
Int'l Holdings BV. He is also Chairman of IMD Business School
and Chairman of Nomoko AG.
Leif Johansson, AstraZeneca Chair said: "I am delighted that Michel
will succeed me following the 2023 AGM. He is an
internationally respected leader with extensive experience in
strategy, planning, execution, governance and corporate stewardship
and a proven track record leading multinational companies, as well
as experience of the pharmaceutical industry gained at Baxter and
as a member of the AstraZeneca Board. I look forward to
undertaking a comprehensive handover in the coming months and to
seeing the continued development and success of
AstraZeneca."
Michel Demaré, AstraZeneca Chair-designate said: "I could not
be prouder to be named Chair-designate of the Board of AstraZeneca
and am excited to have the opportunity to build on Leif's success
as Chair and work with Pascal and members of the Board and Senior
Executive Team when I take on my new role in 2023."
Notes
Biography and photograph:
https://www.astrazeneca.com/our-company/leadership.html#board
Remuneration:
Effective 1 May 2023, the fee for the Chair of the Board will be
£800,000 per annum, paid wholly in cash. The Chair's fee
was last increased in January 2018.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
29 July 2022
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|